VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC

Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to determine the efficacy of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter